Effects of Interleukin-1β and Tumor Necrosis Factor-α on Macrophage Inflammatory Protein-3α Production in Synovial Fibroblast-like Cells from Human Temporomandibular Joints
Overview
Affiliations
Background: Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) are key mediators of the intracapsular pathological conditions of the temporomandibular joint (TMJ). Therefore, the gene expression profiles in synovial fibroblast-like cells (SFCs) from patients with internal derangement of the TMJ were examined after they were stimulated with IL-1β or TNF-α to determine which genes were altered.
Methods: Ribonucleic acid was isolated from SFCs after IL-1β or TNF-α treatment. Gene expression profiling was performed using oligonucleotide microarray analysis. On the basis of the results of this assay, we investigated the kinetics of macrophage inflammatory protein-3α (MIP-3α) gene expression using PCR, and protein production in TMJ SFCs stimulated by IL-1β or TNF-α using an ELISA. Inhibition experiments were performed with MAPK and NFκB inhibitors. SFCs were stimulated with IL-1β or TNF-α after treatment with inhibitors. The MIP-3α levels were measured using an ELISA.
Results: Macrophage inflammatory protein-3α was the gene most upregulated by IL-1β- or TNF-α stimulation. The mRNA and protein levels of MIP-3α increased in response to IL-1β in a time-dependent manner. In contrast, during TNF-α stimulation, the MIP-3α mRNA levels peaked at 4 h, and the protein levels peaked at 8 h. In addition, the IL-1β- and TNF-α-stimulated MIP-3α production was potently reduced by the MAPK and NFκB signaling pathway inhibitors.
Conclusion: Interleukin-1β and TNF-α increased the MIP-3α production in SFCs via the MAPK and NFκB pathways. These results suggest that the production of MIP-3α from stimulation with IL-1β or TNF-α is one factor associated with the inflammatory progression of the internal derangement of the TMJ.
Potential pathological and molecular mechanisms of temporomandibular joint osteoarthritis.
Juan Z, Xing-Tong M, Xu Z, Chang-Yi L J Dent Sci. 2023; 18(3):959-971.
PMID: 37404608 PMC: 10316511. DOI: 10.1016/j.jds.2023.04.002.
Zhang P, Liu Y, Jia L, Ci Z, Zhang W, Liu Y Front Cell Dev Biol. 2021; 9:630678.
PMID: 33816478 PMC: 8010669. DOI: 10.3389/fcell.2021.630678.
Yuan J, Ding W, Wu N, Jiang S, Li W Biomed Res Int. 2020; 2019:2629791.
PMID: 32083119 PMC: 7011344. DOI: 10.1155/2019/2629791.
Tohidnezhad M, Bayer A, Rasuo B, Hock J, Kweider N, Fragoulis A Mediators Inflamm. 2018; 2017:1046438.
PMID: 29348703 PMC: 5733972. DOI: 10.1155/2017/1046438.
Sun Q, Wu G, Chen H, Chen L, Chen H, Zhu G Oncotarget. 2017; 8(36):60312-60323.
PMID: 28947973 PMC: 5601141. DOI: 10.18632/oncotarget.19294.